FORT WAYNE, IN – BioPoly LLC announced today that another US patent has been granted, the second in as many months. The current patent protects the implantation method of its unique BioPoly®partial resurfacing devices. The broad BioPoly patent portfolio is part of the Company’s overall IP strategy to protect its medical device technology as it markets products on a global basis.BioPoly has received CE mark approval on multiple applications of its resurfacing technology in multiple joints (knee, patella, and shoulder systems of products). With more than 4 years of positive clinical experience in Europe, the Company is in process of expanding its product offerings and territories through its global distribution partner, OrthoD – headquartered in the UK. “We are very excited as continue to execute our strategic intellectual property plan so that we can globally expand BioPoly and provide surgeons with even more options for patients,” said Herb Schwartz Ph.D., BioPoly President. The BioPoly® material technology is unique because it combines an orthopaedic polymer (i.e. ultra-high molecular weight polyethylene or UHMWPE) with a lubricating molecule, hyaluronic acid, resulting in an ultra-biocompatible material that is cartilage-friendly. BioPoly® implants are, therefore, used to simply replace the damaged cartilage surface in joints instead of the entire joint. The result is that patients can quickly return to a pain-free, active lifestyle. BioPoly products are available in Europe and parts of Asia; however, they have not yet been approved for use in the US.
About BioPoly LLC
BioPoly LLC is an ISO 13485 certified orthopaedic implant manufacturer located in Fort Wayne, Indiana. The Company is developing, manufacturing and marketing products for use in sports medicine, orthopaedics, and spinal markets. Additional medical applications of the BioPoly® technology in cardiovascular and trauma markets are also being pursued.
